Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNIVERSITE DE RENNES currently maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This portfolio is characterized by a complete distribution of its workload, as the 2 pending office actions are assigned to 2 distinct examiners. This arrangement ensures that the university's intellectual property is being evaluated by multiple sets of eyes, rather than being concentrated under a single examiner's review.
The prosecution activity is further divided across 2 distinct art units, which indicates that the pending applications cover diverse technical ground within the pharmaceutical sector. LANDSMAN, ROBERT S serves as the busiest examiner for the university, overseeing 1 busiest examiner pending office action. This means that LANDSMAN, ROBERT S is responsible for exactly 1 of the total 2 pending office actions currently active for the institution.
Practitioners should note that the use of 2 distinct examiners across 2 distinct art units necessitates a flexible prosecution strategy. Because 1 busiest examiner pending office action is the maximum load for any single examiner, the university's overall progress is not overly sensitive to the pace of one individual. This distribution across 2 distinct art units also means that the university must navigate the specific procedural nuances of two different departments within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921792 | ANTIBODY AND USES THEREOF | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906268 | NEW STRATEGY TO TREAT AND PREVENT DISEASES CAUSED BY ENTEROBACTERIAE | ARMATO JR, DENNIS IGNATIUS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921792 | ANTIBODY AND USES THEREOF | LANDSMAN, ROBERT S | — |
| 17906268 | NEW STRATEGY TO TREAT AND PREVENT DISEASES CAUSED BY ENTEROBACTERIAE | ARMATO JR, DENNIS IGNATIUS | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921792 | ANTIBODY AND USES THEREOF | LANDSMAN, ROBERT S | 1647 | §112 | Final Rejection | — | Pending | Oct 27, 2022 |
| 17906268 | NEW STRATEGY TO TREAT AND PREVENT DISEASES CAUSED BY ENTEROBACTERIAE | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Final Rejection | — | Pending | Sep 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE RENNES has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert S Landsman has the most, with 1 of UNIVERSITE DE RENNES's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
